News of Note—Zhejiang Huahai Pharmaceutical gets some cash; Merck wins an award


> Zhejiang Huahai Pharmaceutical, whose valsartan APIs have been banned from the U.S. after being found to contain a potential carcinogen, has received a $43 million infusion from the city government of Linhai in the eastern province of Zhejiang, where the company is based. Story

> Sun Pharma has invested Rs 120 crore ($1.6 million) to add a manufacturing line to its plant in Guwahati, India, to produce sterile drugs. Story

> U.K.-based Acacia says it received an FDA complete response letter for Barhemsys, its drug candidate for post-operative nausea and vomiting, after the agency identified a deficiency with its contract manufacturer during a pre-approval inspection. Release

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> Merck Research Laboratories has received a Green Chemistry Challenge Award from the American Chemical Society for its sustainable approach to the development and manufacturing of doravirine—a compound recently approved by the FDA for the treatment of HIV. Release

> Quotient Sciences has invested $15 million in a 45,000-square-foot facility near Philadelphia for early-phase formulation development and clinical trial manufacturing. Release

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.